Xian Janssen shifts two brands to Bates141

BEIJING - Bates141 has secured the creative duties for two of Johnson & Johnson subsidiary Xian Janssen Pharmaceutical's over-the-counter products, following a pitch contested by two other agencies.

by | 09/10/2008

DMG was the incumbent for Motilium, which has a reported media spend of US$30 million, though it could not be confirmed whether it attempted to defend the account.

Motilium (a stomach motility drug) is currently the most successful OTC medication across categories in China. The second brand, Mylanta, is a new antacid.

Related Articles

Running against the giants: Can On outpace Nike and Adidas in Asia?

By Matthew Keegan

Crocs uses dancing mannequins to show the human side of the brand

By Kyle O’Brien

Inside Campaign Connect Indonesia: what matters to Indonesian marketers

By Staff Reporters

Bling bling: Exploring the landscape of luxury in India

Why Dentsu’s next buyer can’t look like Havas or the industry it’s leaving behind

By Humphrey Ho

Is it time for Asia’s creators to unionise?

Will AI avatars boost or challenge the future of live commerce?

By Matthew Keegan

Zoom is still in the room: Global CMO Kim Storin's plans to 'disrupt itself' and make APAC its growth engine

By Nikita Mishra

Finding the lost love between marketing and procurement

By Robert Sawatzky

TrinityP3's new AI matchmaking tool lets marketers run their own pitches

By Staff Reporters